Remote patient monitoring in 2026: overview
Remote patient monitoring uses digital devices and communication technologies to collect and transmit health data from outside traditional clinical settings. Home blood-pressure cuffs, scales, glucose sensors and implantable cardiac devices can give care teams a view of patients between visits. Its value depends not simply on continuous data, but on validated devices, patient adherence, alert triage and workflows that turn readings into timely action. Device reliability and fragmented data systems remain practical challenges.
Recent work is testing remote monitoring across more conditions and care transitions. In October 2026, a University of Mississippi Medical Center evaluation examined pharmacist-led monitoring for hypertension, while the Heart Failure Cascade Study reported its Phase II and III outcomes study design. In August 2026, an interstitial lung disease trial led by the National Heart, Lung, and Blood Institute set out to assess combinations of home spirometry, pulse oximetry, scales and ePROs. Also in August, PASTEC proposed an open infrastructure for aggregating cardiac-device data and prospectively validating AI, addressing vendor-specific platforms and review workload.
- 1From readings to action: Hypertension and heart-failure studies are testing care models in which clinicians interpret home measurements and act on them, rather than treating device connectivity as the endpoint.
- 2Data infrastructure matters: PASTEC’s proposed open cardiac-monitoring infrastructure targets data fragmentation and review burden that can limit the practical use of AI.
- 3Monitoring is broadening: Research on interstitial lung disease is evaluating combinations of home measurements and patient-reported outcomes to find workable monitoring pathways beyond cardiovascular care.
Top organizations working on remote patient monitoring
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to remote patient monitoring. Showing 7 of 3,000 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Medtronic Inc.
Corporate · United States |
Implantable telemetry | PAT 6 · PUB 13 GRANTS 1 · NEWS 1,963 |
-54% | Medtronic’s cardiac implantables support remote follow-up by transmitting device data to care teams. Its portfolio makes it an established participant in remote monitoring of patients with implanted cardiac devices. |
| 2 | 
Philips
Corporate · Netherlands |
Connected home devices | PUB 4 · NEWS 1,166 | -36% | Philips develops patient-monitoring and connected-care systems used to collect health data beyond traditional clinical settings. Research on continuous monitoring after same-day surgery also examines its role in post-discharge care. |
| 3 | 
Abbott Laboratories
Corporate · United States |
Implantable telemetry | PUB 4 · NEWS 1,193 | -51% | Abbott’s leadless pacemakers use telemetry to support remote device follow-up. Recent research examines a conductive communication method for remote monitoring of its Aveir pacemaker systems. |
| 4 | 
GE Healthcare
Corporate · United States |
Connected home devices | NEWS 907 | -97% | GE HealthCare develops patient-monitoring and connected-care technologies that can support care beyond hospital settings. Its monitoring portfolio places it in the broader remote-care ecosystem. |
| 5 | 
Koninklijke Phillips N.V.
Corporate · Netherlands |
Connected home devices | PAT 6 · NEWS 804 | -53% | Koninklijke Philips develops connected health and patient-monitoring systems relevant to remote care, including continuous monitoring used to assess patients after discharge. |
| 6 | 
Boston Scientific Corporation
Corporate · United States |
Implantable telemetry | PUB 12 · NEWS 751 | -56% | Boston Scientific’s implantable cardiac devices support remote follow-up and monitoring. Its cardiac-device portfolio connects it to remote management of patients with rhythm disorders. |
| 7 | 
Iora Health
Corporate · United States |
General | NEWS 501 | +75% | |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 29 total
LusciiNetherlandsLuscii provides a home telemonitoring platform for care teams and patients. Research associated with its approach addresses alert reduction and home blood-pressure monitoring.
ImplicityFranceImplicity’s AI-based platform consolidates remote cardiac-device monitoring and alerts for care teams. Recently, it raised growth funding to expand the platform internationally, including in the United States.
Persei vivariumSpainPersei Vivarium’s Caaring software is being evaluated for remote monitoring of patients receiving oral cancer treatment, heart-failure care, and insulin treatment.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 2,484 total
University of CaliforniaUnited StatesUniversity of California researchers have evaluated contactless vital-sign collection during video visits and studied remote monitoring in care settings, including COVID-19.
Stanford UniversityUnited StatesStanford researchers study remote monitoring in peritoneal dialysis and evaluate combining continuous glucose monitoring with remote care for children with type 1 diabetes.
Harvard UniversityUnited StatesHarvard-affiliated research examines remote care approaches including self-administered pulse oximetry and remote monitoring for high-risk patients, as well as telemonitoring in respiratory care.- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where remote patient monitoring innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 3,000 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Connected home devices | Home devices collect measures such as blood pressure or weight; they are accessible for routine monitoring but depend on correct use, connectivity and consistent data transmission. | 2,712 |
Medtronic Inc., U.S. Food and Drug Administration, Philips |
| Wearable sensors | Wearables collect physiological or activity data during daily life; they support frequent measurement but can face adherence, comfort and signal-quality challenges. | 2,915 |
Medtronic Inc., Philips, U.S. Food and Drug Administration |
| Implantable telemetry | Implantable devices transmit data from cardiac systems for remote follow-up; they provide device-linked information but apply to patients with an implant and require clinical review. | 820 |
Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories |
| Contactless sensing | Contactless systems estimate vital signs without a sensor worn by the patient; they reduce device-handling demands but must establish reliable measurements across real-world settings. | 93 |
U.S. Food and Drug Administration, General Electric, China Medical System Holdings Ltd |
| Mobile and behavioral sensing | Mobile tools use phone-based inputs and behavioral signals to follow symptoms or activity; they can capture daily-life patterns but rely on sustained engagement and meaningful interpretation. | 694 |
U.S. Food and Drug Administration, Medtronic Inc., Omada Health, Inc. |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
Funding indicators include $214.3 million in grants across 184 awards since 2020, plus 29 recorded rounds totaling $25.1 billion. These are broad topic-linked records, so treat the round total as an aggregate signal rather than a clean estimate of remote-monitoring-specific capital.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Oct 2026Remote patient monitoring has quietly moved from hospital pilots into ordinary homes. A blood-pressure cuff, a set of scales, a pulse oximeter or a glucose sensor now sends readings straight to a clinical team…Future Patient
- Sep 2026Remote patient monitoring has a credibility problem that rarely gets named. The promise is elegant — continuous vital signs from a patient at home, streamed to a care team that can intervene before a crisis. The reality…The Healthcare Guys
- Aug 2026Over the past decade, remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) have transformed from emerging technologies into integral components of chronic disease management. Fueled by advances in…HIT Consultant
- Jul 2026DIGITAL HEALTH EVENTS 10th Remote Patient Monitoring Summit 2026 Where healthcare’s biggest names in RPM, wearables, and AI-driven care are gathering this September and why your team should be there too Remote patient…Innovation on Medium
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about remote patient monitoring
What companies are working on remote patient monitoring?
Medtronic Inc., Philips, Abbott Laboratories, GE Healthcare and Boston Scientific Corporation are established participants in remote patient monitoring. Medtronic supports remote follow-up for cardiac implantables, while Philips and GE Healthcare develop patient-monitoring and connected-care systems. Abbott and Boston Scientific are also associated with remote follow-up for implantable cardiac devices. These companies represent device and connected-care activity, not an exhaustive list of providers.
Which remote patient monitoring startups are notable in 2026?
Luscii, Implicity and Persei Vivarium are notable startups with different monitoring approaches. Luscii provides a home telemonitoring platform, while Implicity consolidates remote cardiac-device monitoring and alerts using AI. Persei Vivarium’s Caaring software is being evaluated for remote monitoring in cancer treatment, heart-failure care and insulin treatment. Their profiles indicate varied areas of activity, not a ranking of commercial prospects.
Which universities and research centers lead remote patient monitoring research?
The University of California, Stanford University and Harvard University are prominent research organizations, with 76, 96 and 91 documents respectively in the topic window. University of California researchers have evaluated contactless vital-sign collection during video visits. Stanford studies remote monitoring in dialysis and diabetes, while Harvard-affiliated work examines pulse oximetry and monitoring for high-risk patients.
How much funding has remote patient monitoring received?
Topic-linked funding indicators report $214.3 million in grants across 184 awards since 2020, alongside 29 recorded rounds totaling $25.1 billion. These figures are broad aggregates associated with the topic and may include funding that is not exclusively for remote patient monitoring. They should not be read as a verified total of investment into dedicated RPM products or companies.
Who holds the most remote patient monitoring patents?
Medtronic Inc. and Koninklijke Phillips N.V. lead the listed patent holders with 6 patents each in the measured window. Biotronik AG and Amneal Pharmaceuticals LLC follow with 5 each. The counts identify the organizations with the highest listed activity in this dataset; they do not indicate patent quality, scope or commercial value.
Is remote patient monitoring patent activity growing?
No: patent activity declined by 40.1% in the last 12 months compared with the previous 12 months, while publications grew by 12.5%. The differing trends suggest research output is increasing even as recent patenting has slowed. Patent activity also varies by approach, so the aggregate change does not mean every monitoring technology is following the same trajectory.
What are the latest developments in remote patient monitoring?
Recent developments include a hypertension evaluation from the University of Mississippi Medical Center in October 2026 and an open cardiac-data infrastructure proposal from PASTEC in August 2026. The former examines pharmacist-led remote monitoring; the latter targets data aggregation and prospective AI validation across cardiac-device systems. An interstitial lung disease trial in August 2026 is also assessing combinations of home spirometry, pulse oximetry, scales and ePROs.
What are the main approaches in remote patient monitoring?
The main approaches are connected home devices, wearable sensors, implantable telemetry, contactless sensing, and mobile and behavioral sensing. Home devices can collect measures such as blood pressure, while implantable telemetry supports remote follow-up of cardiac devices. Wearables and mobile tools capture signals during daily life; contactless systems avoid worn sensors. Each approach trades measurement continuity or convenience against adherence, signal quality and clinical interpretation.
Which countries lead remote patient monitoring?
The United States leads with 46,836 topic-linked documents, followed by the United Kingdom with 15,781 and Germany with 13,625. Japan and India also have substantial activity, with 11,136 and 11,064 documents respectively. These country counts describe recorded activity in the dataset; they do not measure market adoption or compare healthcare-system performance.
What are the applications of remote patient monitoring?
Applications include cardiovascular care (4,770 documents), older adult and home care (2,969), respiratory care (1,598), diabetes management (1,551) and post-acute care (1,190). Recent research also examines monitoring for interstitial lung disease, home dialysis, pregnancy and neuromuscular disease. These uses rely on choosing measures and response pathways suited to the condition and care setting.